Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference [Yahoo! Finance]
Unicycive Therapeutics, Inc. (UNCY)
Company Research
Source: Yahoo! Finance
clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two presentations related to UNI-494 will be presented at the 29 th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024 taking place March 12-15, 2024, in San Diego, CA. Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “We are looking forward to presenting data on the efficacy of our second clinical stage program UNI-494 in animal models of delayed graft function, a manifestation of acute kidney injury (AKI) that occurs during kidney transplantation resulting in loss of kidney function. We are also presenting a poster describing our ongoing Phase 1 clinical trial design for UNI-494 in healthy volunteers. Based on the results from this trial, we will determine the best path forward for the program. While our primary focus is on advancing our lead drug, OLC (Oxylanthanum Carbonate) towards a New
Show less
Read more
Impact Snapshot
Event Time:
UNCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UNCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UNCY alerts
High impacting Unicycive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
UNCY
News
- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.MarketBeat
- Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference [Yahoo! Finance]Yahoo! Finance
- Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceGlobeNewswire
- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.MarketBeat
- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock.MarketBeat
UNCY
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- UNCY's page on the SEC website